BofA lowered the firm’s price target on Werewolf Therapeutics (HOWL) to $9 from $10 and keeps a Buy rating on the shares. While stating that “there wasn’t much new from Werewolf’s 1Q print,” the firm still sees reasons to be encouraged about the second half outlook, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOWL:
- Werewolf Therapeutics Receives Nasdaq Deficiency Notice
- Strategic Expansion and Clinical Potential of Werewolf Therapeutics’ PREDATOR Platform Boosts Buy Rating
- Werewolf Therapeutics price target lowered to $6 from $8 at Wedbush
- Werewolf Therapeutics Reports Q1 2025 Financial Results
- Werewolf Therapeutics files $150M mixed securities shelf